Clobetasone Butyrate

How to order Clobetasone Butyrate

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Clobetasone Butyrate on Prescriptsy

Clobetasone Butyrate is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Clobetasone butyrate is a moderately potent topical corticosteroid widely used in the United Kingdom for the treatment of eczema, contact dermatitis, atopic dermatitis, and other inflammatory skin conditions that respond to corticosteroid therapy.

It is the active ingredient in Eumovate, one of the most recognised dermatological brands in UK pharmacy practice.

Clobetasone butyrate 0.05% cream is notable for being one of the few topical corticosteroids available over the counter (as a pharmacy medicine) in the UK, providing adults with accessible relief for mild to moderate eczema flares without the need for a GP appointment.

Eczema affects approximately 1 in 5 children and 1 in 10 adults in the UK, making it one of the most common reasons for dermatological consultation in primary care.

Effective management requires a combination of regular emollient use, avoidance of triggers, and appropriate anti-inflammatory treatment during flares.

Clobetasone butyrate occupies a useful position in the topical steroid potency ladder, offering more anti-inflammatory efficacy than mild preparations such as hydrocortisone 1% while carrying a lower risk of local side effects than potent or very potent steroids.

This page provides a comprehensive clinical overview of clobetasone butyrate, including how it works, correct application technique, dosing guidance, side effects, safety warnings, and how to obtain it in the UK.

Important safety information about clobetasone butyrate

Before reading further, note the following key safety points about clobetasone butyrate.

• Apply thinly to affected areas only. Do not use on unaffected skin or as a general moisturiser.
• Do not use on infected skin unless the infection is being treated at the same time with an appropriate antimicrobial agent.
• Avoid prolonged continuous use, especially on the face, flexures (skin folds), and in children, as these areas and populations are more susceptible to corticosteroid side effects.
• Always use emollients as the foundation of your eczema management, with clobetasone butyrate reserved for flare periods.

What is eczema

Eczema (also called dermatitis) is a group of conditions characterised by inflamed, itchy, red, dry, and sometimes blistered or weeping skin.

Atopic eczema (atopic dermatitis) is the most common form, typically beginning in infancy or childhood and associated with a genetic predisposition to allergic conditions including asthma and hay fever (the atopic triad).

Contact dermatitis occurs when the skin reacts to a specific irritant (irritant contact dermatitis) or allergen (allergic contact dermatitis).

The underlying pathology of atopic eczema involves a defective skin barrier (often related to filaggrin gene mutations), which allows increased transepidermal water loss and penetration of allergens and irritants.

This triggers an immune-mediated inflammatory response dominated by type 2 helper T cells (Th2), resulting in the characteristic clinical features of itching, erythema, oedema, and scaling.

Scratching further damages the skin barrier, creating an itch-scratch cycle that perpetuates the condition.

Eczema in the UK

The UK has one of the highest prevalence rates of atopic eczema in the world.

According to the National Eczema Society, approximately 6.6 million adults and 1.3 million children live with eczema in the UK.

The condition significantly impacts quality of life, affecting sleep, concentration, social confidence, and mental health.

NICE guideline CG57 (Atopic eczema in under 12s) and NICE CKS on eczema provide evidence-based recommendations for the stepped management of eczema in both children and adults.

How clobetasone butyrate works: mechanism of action

Clobetasone butyrate is a synthetic fluorinated glucocorticoid that acts by binding to intracellular glucocorticoid receptors in keratinocytes, fibroblasts, and immune cells in the skin.

The activated drug-receptor complex translocates to the cell nucleus, where it modulates the transcription of numerous genes involved in the inflammatory and immune response.

The principal anti-inflammatory effects include suppression of the production of pro-inflammatory cytokines (including interleukins IL-1, IL-6, and TNF-alpha), inhibition of phospholipase A2 (reducing prostaglandin and leukotriene synthesis), decreased vascular permeability and oedema formation, reduced migration of neutrophils and monocytes into inflamed tissue, stabilisation of lysosomal membranes, and suppression of fibroblast proliferation.

These combined effects reduce erythema, swelling, exudation, and itching.

Clobetasone butyrate also has a vasoconstrictive effect on dermal blood vessels, which contributes to its anti-inflammatory action and forms the basis of the vasoconstriction assay used to classify topical steroid potency.

Its moderate potency classification reflects a balance between meaningful clinical efficacy and a relatively low propensity for causing skin atrophy compared with potent and very potent agents.

This makes it a suitable choice for moderate eczema flares, for use on sensitive sites such as the face and flexures (for short courses), and as a step-down from potent steroids after initial disease control.

Topical corticosteroid potency ladder

The BNF classifies topical corticosteroids into four potency groups. Understanding where clobetasone butyrate sits in this hierarchy helps patients and prescribers select the appropriate treatment strength for each clinical situation.

• Mild (Group I): hydrocortisone 0.5% to 1%. Suitable for mild eczema, sensitive areas, and long-term maintenance in some patients.
• Moderate (Group II): clobetasone butyrate 0.05% (Eumovate). Suitable for moderate eczema, short-term use on the face and flexures, and when hydrocortisone provides insufficient control.
• Potent (Group III): betamethasone valerate 0.1% (Betnovate), mometasone furoate 0.1%. Used for more severe or resistant eczema on the body and limbs under medical supervision.
• Very potent (Group IV): clobetasol propionate 0.05% (Dermovate). Reserved for severe, resistant eczema or specific dermatoses under specialist supervision.

The general principle is to use the lowest effective potency for the shortest effective duration, stepping up only when lower-potency agents are insufficient and stepping down once control is achieved.

Clinical evidence and NICE guidance

NICE guideline CG57 recommends a stepped approach to topical corticosteroid use in children with atopic eczema, starting with mild potency for the face and flexures and moderate potency for eczema on other body sites that has not responded to mild preparations.

For adults, NICE CKS on eczema recommends moderate-potency topical corticosteroids such as clobetasone butyrate for eczema on the trunk and limbs when mild steroids are insufficient, and for short courses on the face and flexures.

Clinical studies have demonstrated that clobetasone butyrate 0.05% is significantly more effective than placebo in reducing eczema symptoms (erythema, pruritus, lichenification, and excoriation) and is associated with a lower incidence of local atrophogenic effects compared with more potent topical corticosteroids when used at equivalent treatment durations.

Vasoconstriction assays confirm its intermediate potency between hydrocortisone and betamethasone valerate.

How to apply clobetasone butyrate

Correct application technique is important for maximising efficacy while minimising the risk of side effects.

Apply clobetasone butyrate thinly to the affected areas only, once or twice daily, gently rubbing in until absorbed. Do not apply to unaffected skin.

Use the fingertip unit (FTU) system to measure the correct amount.

One FTU is the amount of cream or ointment squeezed from a standard tube (with a 5 mm diameter nozzle) along an adult index finger from the tip to the first crease.

One FTU covers an area equivalent to two adult flat hands (palms and fingers).

Emollients should always be applied as the foundation of eczema management, used liberally and frequently (at least twice daily and after bathing) even when the skin appears clear.

When using both an emollient and clobetasone butyrate, apply the emollient first.

Wait at least 15 to 30 minutes before applying the corticosteroid to avoid diluting it and to ensure optimal skin absorption.

This interval also allows the emollient to begin restoring the skin barrier before the anti-inflammatory agent is applied.

Cream versus ointment

Cream formulations (oil-in-water emulsions) are generally preferred for moist, weeping, or exudative eczema and for use on the face, flexures, and hairy areas, as they spread easily and are cosmetically acceptable.

Ointment formulations (water-in-oil or anhydrous) are more occlusive, providing greater hydration and enhanced drug penetration, making them more suitable for dry, scaly, lichenified, or chronic eczema on the body and limbs.

Your prescriber or pharmacist will recommend the most appropriate formulation based on the type and location of your eczema.

Side effects of clobetasone butyrate

Local side effects

Mild stinging or burning on application is common and usually transient, settling within a few minutes. This is more likely when applying to broken, inflamed, or excoriated skin.

With prolonged or inappropriate use, local skin changes may develop, including skin thinning (atrophy), striae (stretch marks), telangiectasia (visible small blood vessels), easy bruising, perioral dermatitis (a spotty rash around the mouth), acne or worsening of pre-existing acne, hypertrichosis (increased hair growth at the application site), and depigmentation (lightening of skin colour).

These effects are more likely with extended treatment beyond recommended durations, use under occlusive dressings, application to thin-skinned areas (face, eyelids, genitalia, flexures), and in children and elderly patients.

Systemic side effects

Systemic absorption of clobetasone butyrate is generally negligible when used at recommended doses on limited body areas.

However, significant systemic absorption may occur with application over large body surface areas, prolonged uninterrupted use, use under occlusion, application to broken skin, and in infants and young children (who have a high body surface area to weight ratio).

In rare cases, systemic effects may include adrenal suppression, Cushing syndrome features (weight gain, moon face, striae), hyperglycaemia, and growth retardation in children.

Contact sensitisation

Rarely, patients may develop allergic contact dermatitis to the corticosteroid itself or to excipients in the formulation (such as preservatives or fragrances in generic products).

If the condition worsens despite treatment, or if a new pattern of redness and irritation develops at the application site, contact sensitisation should be considered and patch testing may be appropriate.

Warnings and precautions

Infection

Do not apply clobetasone butyrate to skin that is infected with bacteria, fungi (including tinea or candida), or viruses (including herpes simplex or varicella) unless the infection is being treated concurrently with an appropriate antimicrobial agent.

Topical corticosteroids can suppress the local immune response, allowing infections to spread and masking their clinical signs.

Face and flexures

Although clobetasone butyrate is suitable for short-term use on the face and flexures (unlike potent steroids, which should generally be avoided in these areas), treatment on these sites should be limited to 5 to 7 days under medical supervision.

The skin in these areas is thinner and has greater absorption, increasing the risk of atrophy, telangiectasia, and perioral dermatitis.

Children

Children are more susceptible to the systemic effects of topical corticosteroids due to their higher body surface area to weight ratio.

Treatment in children should always be supervised by a prescriber, using the lowest effective potency for the shortest effective duration. Avoid long-term continuous use without regular review.

Growth should be monitored in children receiving prolonged topical corticosteroid treatment.

Topical steroid withdrawal

Prolonged, continuous use of topical corticosteroids can lead to a phenomenon sometimes described as topical steroid withdrawal (TSW), characterised by burning, stinging, and redness that spreads beyond the original treatment area when the steroid is stopped.

If you are concerned about this, discuss tapering strategies with your GP or dermatologist rather than stopping treatment abruptly.

How to get clobetasone butyrate in the UK

Clobetasone butyrate 0.05% cream is available as a pharmacy medicine (P) under the brand name Eumovate for adults aged 12 and over.

You can purchase it from a pharmacist without a prescription for the short-term treatment (up to 7 days) of mild to moderate eczema and dermatitis.

The pharmacist will ask questions about your symptoms and medical history to ensure it is appropriate.

For use in children under 12, for longer treatment courses, for ointment formulations, or for use on the face or genital area, a prescription from a GP or dermatologist is required.

The standard NHS prescription charge in England is currently 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

When to seek medical advice

Consult your GP or pharmacist if your eczema does not improve within 7 days of using clobetasone butyrate, your skin condition worsens or spreads, you develop signs of skin infection (increased redness, warmth, swelling, weeping, crusting, or pain), or you notice skin thinning, stretch marks, or visible blood vessels at the treatment site.

Seek urgent advice (contact NHS 111 or your GP) if you develop widespread or severe eczema flares, eczema herpeticum (a spreading blistered or painful eruption suggesting herpes simplex infection of eczematous skin), or signs of systemic unwellness.

Report any suspected adverse reactions via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk .

Sources

• Eumovate Cream, Summary of Product Characteristics (EMC)
• Clobetasone butyrate, British National Formulary (BNF)
• NICE CG57: Atopic eczema in under 12s
• NICE CKS: Eczema, atopic
• Atopic eczema, NHS
• MHRA Yellow Card Scheme